One factor that could contribute to the selection of CST3 in CVD is metronidazole and/or other BV medications, as previously demonstrated by the results of topical treatment in patients with BV (Ferris et al., 2007; Jakobsson and Forsum, 2007; Brooks et al., 2017b). This evidence concerns the gene CST3 and bacterial vaginosis.